Lonza Collaborates with Takeda to Bring Cancer Treatment to Patients
(WorldNews Switzerland)

European Commission approved ALUNBRIG® (brigatinib), once-daily tablet for adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. The Lonza team in Tampa, FL (USA) collaborated with Takeda to provide support from early drug product development studies through commercial...